Nabi Biopharma (NABI) Says Second NicVAX(R) Phase III Trial Failed to Meet Primary Endpoint; Reviewing Strategic Alternatives
Up)
Nabi Biopharma (Nasdaq: NABI) reports results of second NicVAX(R) Phase III clinical trial failed to meet the primary endpoint.
The company said it is now reviewing strategic alternatives, and has hired Piper Jaffray.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
The company said it is now reviewing strategic alternatives, and has hired Piper Jaffray.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
You May Also Be Interested In
- UPDATE: Angelo, Gordon to Acquire Benihana (BNHN) for $16.30/Share in Cash
- UPDATE: SAP's (SAP) America Unit to Buy Ariba (ARBA) for $45/Share
- KKR (KKR) Said to Be in Talks with Delek Group for Phoenix Holdings Stake
Create E-mail Alert Related Categories
FDA, Mergers and Acquisitions, Trading HaltsRelated Entities
Piper JaffraySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
